CHANNELS

Aerospace

Automotive

Automated & Autonomous Vehicles

Battery & Electrification Technology

Defense

Drone TV

Electronics

Manufacturing & Prototyping

Materials

Medical

Motion Control

RF & Microwave Technology

Robotics & Automation

Sensors & IoT

Test & Measurement

Aerospace
Automotive
Automated & Autonomous Vehicles
Battery & Electrification Technology
Defense
Drone TV
Electronics
Manufacturing & Prototyping
Materials
Medical
Motion Control
RF & Microwave Technology
Robotics & Automation
Sensors & IoT
Test & Measurement
Aerospace & Defense
Search Results

Why Omalizumab Has the Potential to Be a ‘Life-Changing’ Food Allergy Medication

Watch this video to see Robert Wood, Director of Pediatric Allergy and Immunology at Johns Hopkins, discuss results that suggest omalizumab has the potential to be a ‘life-changing’ medication for patients with food allergy, including those with multiple food allergies.

"The day-to-day life of patients with food allergy is consumed by fear of accidental exposure to food allergens," says Robert Wood  , director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children's Center, and the study's principal investigator. "Our findings have the potential to be very meaningful, and potentially even life-changing, for people with food allergies."

Topics:
Medical

More From SAE Media Group

    Transcript

    00:00:00 [MUSIC] >> Hi. My name is Dr. Robert Wood, and I'm Director of the Division of Pediatric Allergy, Immunology, and Rheumatology here at the Johns Hopkins Children's Center. I'm here to talk to you today about exciting new study that we recently published on the treatment for food allergy. Now, why is this important?

    00:00:29 The reality is we have not had treatment for food allergy. For time eternity, we have told our patients to avoid what they're allergic to and to carry emergency medications to use in the event of an accidental exposure. We had the opportunity in this new study to look at a drug called Xolair, a drug that's actually been approved to treat asthma for over 20 years for its potential benefit in treating food allergy. We've done some small studies to

    00:00:56 suggest that it probably did work, probably worked very well. But we had to do the right study to have the opportunity to bring this treatment through FD approval to our patients. The OUtMATCH study, which is what we called this trial, enrolled 180 children and adults, mostly age 17 and below, and treated them with Xolair after doing baseline food challenges to assess their level of allergy to peanut and at least two other foods,

    00:01:26 including milk, egg, wheat, cashew, walnut, and hazelnut. This is an injectable therapy and the patients received injections every two weeks or every four weeks over the next 16 weeks, after which they underwent another set of food challenges to determine if their level of reaction to each food was changed by the treatment with Xolair compared to placebo. We found very positive results. As an example, for peanut,

    00:01:56 67 percent of those treated with the real drug compared to placebo could tolerate a moderate to large amount of peanut without having a reaction. The same turned out to be true for all of the six other foods, seeing a very significant difference between the real drug and placebo. We've been very fortunate now to not just publish this paper, but to see this drug go through the FD approval process so that we actually have accomplished our original goal,

    00:02:27 was to bring this potentially life-changing therapy to our patients with food allergy. We expect that this will be a real difference maker for many of the 17 million Americans who suffer from true food allergy. [MUSIC]